Skip to main content
DNA Labs India

Pediatric ALL Panel - Karyotyping + MLPA Deletion/Duplication + FISH Panel Test

DNA Labs India | ISO 9001:2015 Certified

Pediatric ALL Panel - Karyotyping + MLPA Deletion/Duplication + FISH Panel Test

Short Name: Ped ALL Panel

Also known as: Pediatric Acute Lymphoblastic Leukemia Genetic Panel, Childhood ALL Chromosomal and Molecular Panel, Ped ALL Comprehensive Genetic Panel

Pediatric ALL Panel - Karyotyping + MLPA Deletion/Duplication + FISH Panel Test test available at DNA Labs India for ₹24,000. Uses Cell Culture and G-banding (Karyotyping), MLPA (Multiplex Ligation-dependent Probe Amplification), FISH (Fluorescence In Situ Hybridization) on Peripheral Blood or Bone Marrow samples. Results in Results are typically available within 7-10 business days from the date of sample receipt at the laboratory. Results will be delivered via the online portal, email, or WhatsApp as per the patient's preference.. Free home collection in 300+ cities across India.

Genetic PanelPediatric (0-18 years)🏠 Home Collection

✍️ Written By

🩺 Medically Reviewed By

Dr SULOCHANA HEMCHANDRA HOLLA

Dr SULOCHANA HEMCHANDRA HOLLA

Consultant Medical Geneticist · Reg: 8532

Last reviewed: September 7, 2026

Overview

The purpose of the Pediatric ALL Panel is to detect and characterize the genetic abnormalities associated with Pediatric Acute Lymphoblastic Leukemia (ALL). This panel aids in confirming the diagnosis of ALL, identifying specific chromosomal translocations, deletions, and duplications, determining the risk category (standard, intermediate, or high risk), guiding treatment decisions including the use of targeted therapies, and monitoring for minimal residual disease markers. Accurate genetic characterization is essential for personalized treatment planning and improved outcomes in children with ALL.

Test Code
3166
ICD Code
C91.0
Price
₹24,000
Sample Type
Peripheral Blood or Bone Marrow
Result Time
Results are typically available within 7-10 business days from the date of sample receipt at the laboratory. Results will be delivered via the online portal, email, or WhatsApp as per the patient's preference.
Fasting Required
No
Method
Cell Culture and G-banding (Karyotyping), MLPA (Multiplex Ligation-dependent Probe Amplification), FISH (Fluorescence In Situ Hybridization)
Step 1

Sample Collection

A doctor's prescription is required. Inform the healthcare team about any medications the child is currently taking, any bleeding disorders, or allergies. No fasting is required for peripheral blood collection. For bone marrow aspiration, specific preparation instructions will be provided by the treating physician. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Method: Venipuncture (Peripheral Blood) or Bone Marrow Aspiration

Step 2

Laboratory Analysis

For peripheral blood: A trained phlebotomist will collect 2-3 mL of blood in an EDTA vacutainer and 2-3 mL in a Sodium Heparin vacutainer via venipuncture from a vein in the arm or hand. For bone marrow aspiration: The procedure is performed by a physician, typically aspirating marrow from the posterior iliac crest under local anesthesia or conscious sedation. The child may feel brief pressure or discomfort during aspiration.

Step 3

Report Delivery

For peripheral blood collection: Apply gentle pressure to the puncture site with a cotton ball for 3-5 minutes. A small bandage will be placed. For bone marrow aspiration: A sterile dressing will be applied to the aspiration site. The child should avoid strenuous physical activity for 24-48 hours. Mild soreness at the aspiration site is normal and typically resolves within a few days. Contact the physician if there is persistent pain, swelling, redness, or fever.

Timeline: Results are typically available within 7-10 business days from the date of sample receipt at the laboratory. Results will be delivered via the online portal, email, or WhatsApp as per the patient's preference.

Patient Instructions

1
Before the Test:A doctor's prescription is required for this test. Inform the healthcare team about any medications the child is currently taking, any known bleeding disorders, or allergies. No fasting is required for peripheral blood collection. For bone marrow aspiration, specific preparation instructions will be provided by the treating physician. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
2
During the Test:For peripheral blood collection: A trained phlebotomist will draw 2-3 mL of blood from a vein in the child's arm or hand using a needle and vacutainer system. Two separate vacutainers will be used — one with EDTA anticoagulant and one with Sodium Heparin. The procedure typically takes 5-10 minutes. For bone marrow aspiration: A physician will perform the procedure, usually aspirating marrow from the posterior iliac crest (hip bone) under local anesthesia or conscious sedation. The child may feel brief pressure or a dull ache during aspiration. The procedure typically takes 15-30 minutes.
3
After the Test:For peripheral blood: Apply gentle pressure to the puncture site for 3-5 minutes. A bandage will be applied. The child can resume normal activities immediately. For bone marrow aspiration: A sterile dressing will be applied to the aspiration site. Avoid strenuous physical activity for 24-48 hours. Mild soreness at the aspiration site is normal and typically resolves within a few days. Over-the-counter pain relief may be used as recommended by the physician. Contact the healthcare provider if there is persistent pain, swelling, redness, drainage, or fever at the aspiration site.

About This Test

Who Should Get This Test

The purpose of the Pediatric ALL Panel is to detect and characterize the genetic abnormalities associated with Pediatric Acute Lymphoblastic Leukemia (ALL). This panel aids in confirming the diagnosis of ALL, identifying specific chromosomal translocations, deletions, and duplications, determining the risk category (standard, intermediate, or high risk), guiding treatment decisions including the use of targeted therapies, and monitoring for minimal residual disease markers. Accurate genetic characterization is essential for personalized treatment planning and improved outcomes in children with ALL.

How to Prepare

  • Collect 2-3 mL peripheral blood or bone marrow in an EDTA vacutainer
  • Collect 2-3 mL peripheral blood or bone marrow in a Sodium Heparin vacutainer
  • Label both vacutainers clearly with patient name, date of birth, and sample ID
  • Maintain samples at ambient temperature (18-25°C); do not refrigerate or freeze
  • Transport samples to the laboratory within 24-48 hours of collection
  • Ensure samples are not hemolyzed, clotted, or contaminated
  • Include the doctor's prescription and completed test requisition form with the samples

Doctor's Notes

Reviewed by — MBBS, MD (Medical Genetics) · Reg. No. 8532

"The Pediatric ALL Panel is an indispensable tool in the management of childhood Acute Lymphoblastic Leukemia. By combining karyotyping, MLPA, and FISH, this panel identifies critical genetic abnormalities such as the Philadelphia chromosome t(9;22), ETV6-RUNX1 fusion, IKZF1 deletions, and ploidy status that directly influence risk stratification and treatment decisions. Identifying high-risk features like BCR-ABL1 positivity or IKZF1 deletions early allows oncologists to intensify therapy or incorporate targeted agents such as tyrosine kinase inhibitors, significantly improving outcomes. I strongly recommend this panel for every child diagnosed with ALL as part of the initial diagnostic workup."

Last medically reviewed: September 7, 2026

Test Parameters & Specifications

Sample TypePeripheral Blood or Bone Marrow
Sample Volume2-3 mL each in EDTA and Sodium Heparin vacutainers
ContainerEDTA Vacutainer (2-3 mL) and Sodium Heparin Vacutainer (2-3 mL)
Collection MethodVenipuncture (Peripheral Blood) or Bone Marrow Aspiration

Sample Stability

Peripheral Blood (EDTA)
Peripheral Blood (Sodium Heparin)
Bone Marrow (EDTA)
Bone Marrow (Sodium Heparin)
Sample Rejection Criteria:
  • Clotted sample
  • Hemolyzed sample
  • Insufficient sample volume (less than 2 mL per vacutainer)
  • Sample collected in incorrect anticoagulant
  • Sample older than 48 hours at ambient temperature
  • Unlabeled or mislabeled samples
  • Samples without a valid doctor's prescription or requisition form

Understanding Your Results

The results of the Pediatric ALL Panel provide critical genetic information that aids in the diagnosis, classification, risk stratification, and treatment planning for Pediatric Acute Lymphoblastic Leukemia. Each component of the panel contributes unique and complementary information. Results should always be interpreted by a qualified hematologist or oncologist in the context of clinical findings, complete blood count, peripheral smear, bone marrow morphology, and flow cytometry immunophenotyping results.
📊

No numerical or structural chromosomal abnormalities detected. Standard risk classification may apply pending other genetic and clinical findings.

📊

Associated with favorable prognosis in pediatric B-cell ALL. Commonly involves gain of chromosomes 4, 6, 10, 14, 17, 18, and 21.

📊

Associated with poor prognosis. Near-haploidy (23-29 chromosomes) carries the worst outcome among ALL subtypes.

📊

Indicates Ph-positive ALL, classified as high-risk. Targeted therapy with tyrosine kinase inhibitors (e.g., imatinib, dasatinib) in combination with chemotherapy is recommended. Allogeneic stem cell transplantation may be considered.

📊

Generally associated with favorable prognosis in pediatric B-cell ALL. These patients typically respond well to standard chemotherapy protocols.

📊

Associated with pre-B cell ALL. With contemporary treatment protocols, outcomes have improved significantly.

📊

Associated with infant ALL and certain childhood ALL subtypes. Generally carries a poor prognosis and may require intensified therapy or stem cell transplantation.

📊

Associated with poor prognosis, higher risk of relapse, and inferior event-free survival. May warrant treatment intensification.

📊

Frequently observed in ALL. May be associated with higher risk disease depending on co-occurring genetic abnormalities.

📊

Classified as high-risk ALL. Patients benefit from intensified chemotherapy regimens.

⚠️ When to Consult a Doctor:

Consult your pediatric oncologist or hematologist immediately if your child presents with persistent unexplained fever, unusual fatigue or pallor, bone or joint pain, easy bruising or bleeding, frequent or recurrent infections, unintentional weight loss, loss of appetite, or painless swelling of lymph nodes in the neck, armpits, or groin. Early diagnosis and timely initiation of treatment are critical for achieving favorable outcomes in pediatric Acute Lymphoblastic Leukemia.

Limitations

  • ⚠Karyotyping may not detect submicroscopic genetic changes smaller than 5-10 Mb
  • ⚠Cryptic translocations may not be visible on conventional cytogenetic analysis
  • ⚠MLPA detects deletions and duplications but cannot identify balanced translocations or point mutations
  • ⚠FISH is limited to the specific probes used and may not detect all possible genetic abnormalities
  • ⚠Results must be interpreted in conjunction with clinical findings, immunophenotyping, and other laboratory data
  • ⚠This panel does not replace the need for flow cytometry immunophenotyping or molecular studies such as BCR-ABL1 quantitative PCR
  • ⚠False-negative results may occur if the abnormal clone is present in very low proportion

Risks & Considerations

  • ●For peripheral blood collection: Minor bruising or hematoma at the needle insertion site, slight pain during venipuncture, very rare risk of infection at the puncture site
  • ●For bone marrow aspiration: Pain or discomfort at the aspiration site during and after the procedure, minor bleeding or bruising at the aspiration site, rare risk of infection, very rare risk of injury to surrounding structures
  • ●Emotional distress related to the diagnostic process and waiting for results
  • ●Risk of false-negative or inconclusive results requiring repeat testing

Interfering Factors

  • ●Delayed sample processing beyond 48 hours may reduce cell viability and affect karyotyping results
  • ●Prior chemotherapy or radiation therapy may suppress cell growth in culture, leading to insufficient metaphases for analysis
  • ●Hemolyzed or clotted samples are not suitable for testing
  • ●Contaminated samples may yield unreliable results
  • ●Use of incorrect anticoagulant may affect cell morphology and culture viability

Compare With Similar Tests

TestPediatric ALL Panel - Karyotyping + MLPA Deletion/Duplication + FISH PanelKaryotyping AloneMLPA AloneFISH AloneThis Comprehensive Panel (Karyotyping + MLPA + FISH)
ComparisonPediatric ALL Panel - Karyotyping + MLPA Deletion/Duplication + FISH Panel

Frequently Asked Questions

What is the Pediatric ALL Panel?
The Pediatric ALL Panel is a comprehensive genetic diagnostic test that combines three advanced methods — Karyotyping, MLPA (Multiplex Ligation-dependent Probe Amplification) Deletion/Duplication analysis, and FISH (Fluorescence In Situ Hybridization) Panel — to detect chromosomal and genetic abnormalities associated with Pediatric Acute Lymphoblastic Leukemia (ALL). This panel provides essential information for diagnosis, risk stratification, and treatment planning.
Why is genetic testing important for Pediatric Acute Lymphoblastic Leukemia?
Genetic testing is critical for Pediatric ALL because specific chromosomal and molecular abnormalities directly influence the risk classification, prognosis, and treatment approach. For example, the presence of the Philadelphia chromosome (BCR-ABL1) indicates high-risk disease requiring targeted therapy, while ETV6-RUNX1 fusion is associated with favorable prognosis. Identifying these abnormalities allows oncologists to personalize treatment and improve outcomes.
What sample types are accepted for this test?
The Pediatric ALL Panel accepts two sample types: peripheral blood (collected via venipuncture) or bone marrow (collected via bone marrow aspiration). Both samples should be collected in EDTA vacutainers (2-3 mL) and Sodium Heparin vacutainers (2-3 mL). The choice of sample type depends on the clinical situation and will be determined by the treating physician.
How long does it take to receive the results?
Results of the Pediatric ALL Panel are typically available within 7-10 business days from the date of sample receipt at the laboratory. This timeframe accounts for cell culture time required for karyotyping, MLPA processing, and FISH analysis. Results will be delivered via the online portal, email, or WhatsApp.
What is Karyotyping and what does it detect in ALL?
Karyotyping is a laboratory technique that examines the complete set of chromosomes in a cell to identify numerical and structural abnormalities. In the context of ALL, karyotyping can detect hyperdiploidy (more than 50 chromosomes, associated with favorable prognosis), hypodiploidy (fewer than 44 chromosomes, associated with poor prognosis), and structural rearrangements such as translocations. It provides a broad, genome-wide overview of chromosomal changes.
What is MLPA and what genetic changes does it identify?
MLPA (Multiplex Ligation-dependent Probe Amplification) is a molecular technique that detects deletions and duplications (copy number variations) in specific genes. In this panel, MLPA targets genes commonly altered in pediatric ALL, including IKZF1 (IKAROS), PAX5, CDKN2A/B, ETV6, RB1, BTG1, and EBF1. These submicroscopic changes are not visible on conventional karyotyping and provide important prognostic information.
What is FISH and what abnormalities does it detect in ALL?
FISH (Fluorescence In Situ Hybridization) uses fluorescently labeled DNA probes that bind to specific chromosomal regions to detect targeted genetic abnormalities. In this panel, FISH probes detect BCR-ABL1 fusion (Philadelphia chromosome), ETV6-RUNX1 fusion, TCF3-PBX1 fusion, KMT2A (MLL) rearrangements, intrachromosomal amplification of chromosome 21 (iAMP21), and MYC rearrangements. FISH provides rapid and specific detection of these clinically significant abnormalities.
Does my child need to fast before this test?
No, fasting is not required for the Pediatric ALL Panel. If the test involves peripheral blood collection, the child can eat and drink normally before the procedure. If a bone marrow aspiration is planned, the treating physician will provide specific preparation instructions, which may include fasting if sedation is to be used.
Is the bone marrow aspiration procedure painful for the child?
Bone marrow aspiration may cause brief discomfort or a dull aching sensation when the needle is inserted into the bone. The procedure is typically performed under local anesthesia, and conscious sedation may be used for younger children to minimize pain and anxiety. Most children experience only mild soreness at the aspiration site after the procedure, which resolves within a few days. Pain relief measures will be recommended by the physician as needed.
Can this panel help determine the risk category of my child's ALL?
Yes, the Pediatric ALL Panel plays a central role in risk stratification of ALL. The genetic abnormalities detected by karyotyping, MLPA, and FISH are key factors used by oncologists to classify ALL as standard risk, intermediate risk, or high risk. For example, hyperdiploidy and ETV6-RUNX1 fusion are favorable markers, while BCR-ABL1 positivity, IKZF1 deletion, KMT2A rearrangement, and iAMP21 are high-risk markers that may require intensified therapy.
Is home sample collection available for this test?
Yes, DNA Labs India offers free home sample collection for the Pediatric ALL Panel across major cities in India, including Mumbai, Delhi, Bangalore, Hyderabad, Chennai, Kolkata, Pune, Ahmedabad, and many more. A trained phlebotomist will visit your home to collect the peripheral blood sample. However, if a bone marrow aspirate is required, the procedure must be performed at a hospital or clinic by a qualified physician.
What should I do if the test results show genetic abnormalities?
If the Pediatric ALL Panel results reveal genetic abnormalities, it is essential to consult your child's pediatric oncologist or hematologist for detailed interpretation and counseling. The treating physician will integrate the genetic findings with clinical data, bone marrow morphology, and immunophenotyping results to determine the risk category and develop an appropriate, personalized treatment plan. Genetic counseling may also be recommended to discuss the implications of the findings for the child and family.
Worried about the process? Our certified phlebotomists collect thousands of samples every month across India. The process takes under 5 minutes and is virtually painless. Questions? Message us on WhatsApp — we're here 7 days a week.

Related Tests

DPD Gene Mutations (5-FU Toxicity) Detection Test

₹9,828

T-Cell Gene Rearrangement Mutation Detection Test

₹20,000

BCR-ABL Gene Rearrangement PCR Qualitative Test

₹5,000

5-Fluorouracil (5FU) Toxicity Test

₹10,000

CALR Mutation Detection Test

₹6,000

Cancer Targeted Gene Panel: Lung Test

₹27,000
For Hospitals & Clinics

Reference Laboratory Services

We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.

LIMS Integration

Your Data Privacy

Your medical data is protected under Indian law.

✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.

✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.

Book Your Test

Enter your details and we'll connect you within 15 minutes.

🧬

Quick Connect

Enter your mobile number and we’ll connect you with the team.

+91

✅ Connecting you now...

🔒 Your number is used to respond to this request.